Given these considerations, it might be interesting to determine the exact molecular mechanism in distinct types of neuroblastoma cell lines and to evaluate whether combined treatment with idasanutlin and venetoclax could overcome high MCL1 expression in an MCL1-inducible or venetoclax-resistant model system of neuroblastoma. The gene discussed is MCL1; the disease is neuroblastoma.